Open AccessIn Vitro and In Vivo Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris
Author(s) -
Janet Herrada,
Ahmed Gamal,
Lisa Long,
Sonia P. Sanchez,
Thomas S. McCormick,
Mahmoud A. Ghannoum
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00306-21
Subject(s) - fluconazole , amphotericin b , candida auris , in vivo , pharmacology , in vitro , antifungal , microbiology and biotechnology , medicine , biology , biochemistry
Antifungal activity of AmBisome against Candida auris was determined in vitro and in vivo AmBisome showed MIC 50 and MIC 90 values of 1 and 2 μg/ml, respectively. Unlike conventional amphotericin B, significant in vivo efficacy was observed in the AmBisome 7.5 mg/kg treatment group in survival and reduction of kidney tissue fungal burden compared to the untreated group. Our data show that AmBisome has significant antifungal activity against C. auris infection in vitro and in vivo .